Advances in Prostate-Specific Antigen Testing

Advances in Clinical Chemistry

Volumn 41, Issue , 2006, Pages 231-261

  Wu, Ping ^a   Koistinen, Hannu ^a   Finne, Patrik ^a   Zhang, Wan Ming ^a   Zhu, Lei ^a   Leinonen, Jari ^a   Stenman, Ulf Håkan ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33747874392     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2423(05)41007-0     Document Type: Review

References (202)

1. Parkin D., Pisani P., and Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 80 6 (1999) 827-841
2. Stamey T., Yang N., Hay A., McNeal J., Freiha F., and Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317 15 (1987) 909-916
3. Stenman U., Hakama M., Knekt P., Aromaa A., Teppo L., and Leinonen J. Serum concentrations of prostate-specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer. Lancet 344 8937 (1994) 1594-1598
4. Gann P., Hennekens C., and Stampfer M. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 273 4 (1995) 289-294
5. Kramer B., Gohagan J., Prorok P., and Smart C. A National Cancer Institute sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers. Cancer 71 2 Suppl (1993) 589-593
6. Auvinen A., Tammela T., Stenman U., et al. Screening for prostate cancer using serum prostate-specific antigen: A randomised, population-based pilot study in Finland. Br J Cancer 74 4 (1996) 568-572
7. de Koning H., Auvinen A., Berenguer Sanchez A., et al. Large-scale randomized prostate cancer screening trials: Program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial. Int J Cancer 97 2 (2002) 237-244
8. D'Amico A., Chen M., Roehl K., and Catalona W. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351 2 (2004) 125-135
9. Catalona W., Smith D., Ratliff T., et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. [published erratum appears in. N Engl J Med 325 18 (1991) 1324 [see comments.]
10. Catalona W., Smith D., Ratliff T., et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. [published erratum appears in. N Engl J Med 324 17 (1991) 1156-1161
11. Oesterling J. Prostate specific antigen: A critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145 5 (1991) 907-923
12. Hudson M., Bahnson R., and Catalona W. Clinical use of prostate specific antigen in patients with prostate cancer. J Urol 142 4 (1989) 1011-1017
13. Stenman U., Leinonen J., Alfthan H., Rannikko S., Tuhkanen K., and Alfthan O. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res 51 1 (1991) 222-226
14. Lilja H., Christensson A., Dahlen U., et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem 37 9 (1991) 1618-1625
15. Zhang W., Leinonen J., Kalkkinen N., and Stenman U. Prostate-specific antigen forms a complex with and cleaves alpha 1- protease inhibitor in vitro. Prostate 33 2 (1997) 87-96
16. Zhang W., Finne P., Leinonen J., et al. Characterization and immunological determination of the complex between prostate-specific antigen and alpha2-macroglobulin. Clin Chem 44 12 (1998) 2471-2479
17. Zhang W., Finne P., Leinonen J., Vesalainen S., Nordling S., and Stenman U. Measurement of the complex between prostate-specific antigen and alpha1-protease inhibitor in serum (see comments). Clin Chem (1999) 814-821
18. Zhang W., Finne P., Leinonen J., Salo J., and Stenman U. Determination of prostate-specific antigen complexed to alpha(2)-macroglobulin in serum increases the specificity of free to total PSA for prostate cancer. Urology 56 2 (2000) 267-272
19. Zhang W., Finne P., Leinonen J., and Stenman U. Characterization and determination of the complex between prostate-specific antigen and alpha 1-protease inhibitor in benign and malignant prostatic diseases. Scand J Clin Lab Invest 233 Suppl (2000) 51-58
20. Finne P., Zhang W., Auvinen A., et al. Use of the complex between prostate specific antigen and alpha 1-protease inhibitor for screening prostate cancer. J Urol 164 6 (2000) 1956-1960
21. Charrier J., Tournel C., Michel S., et al. Differential diagnosis of prostate cancer and benign prostate hyperplasia using two-dimensional electrophoresis. Electrophoresis 22 9 (2001) 1861-1866
22. Mikolajczyk S., Marker K., Millar L., et al. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res 61 18 (2001) 6958-6963
23. Niemela P., Lovgren J., Karp M., Lilja H., and Pettersson K. Sensitive and specific enzymatic assay for the determination of precursor forms of prostate-specific antigen after an activation step. Clin Chem 48 8 (2002) 1257-1264
24. Mikolajczyk S., Millar L., Wang T., et al. A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res 60 3 (2000) 756-759
25. Nurmikko P., Pettersson K., Piironen T., Hugosson J., and Lilja H. Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146. Clin Chem 47 8 (2001) 1415-1423
26. Mikolajczyk S., Marks L., Partin A., and Rittenhouse H. Free prostate-specific antigen in serum is becoming more complex. Urology 59 6 (2002) 797-802
27. Wang M., Valenzuela L., Murphy G., and Chu T. Purification of a human prostate specific antigen. Invest Urol 17 2 (1979) 159-163
28. Papsidero L., Wang M., Valenzuela L., Murphy G., and Chu T. A prostate antigen in sera of prostatic cancer patients. Cancer Res 40 7 (1980) 2428-2432
29. Kuriyama M., Wang M., Lee C., et al. Use of human prostate-specific antigen in monitoring prostate cancer. Cancer Res 41 10 (1981) 3874-3876
30. Watt K., Lee P., M'Timkulu T., Chan W., and Loor R. Human prostate-specific antigen: Structural and functional similarity with serine proteases. Proc Natl Acad Sci USA 83 10 (1986) 3166-3170
31. Diamandis E., Yousef G., Luo L., Magklara A., and Obiezu C. The new human kallikrein gene family: Implications in carcinogenesis. Trends Endocrinol Metab 11 2 (2000) 54-60
32. Borgono C., Michael I., and Diamandis E. Human tissue kallikreins: Physiologic roles and applications in cancer. Mol Cancer Res 2 5 (2004) 257-280
33. Riegman P., Vlietstra R., Klaassen P., et al. The prostate-specific antigen gene and the human glandular kallikrein-1 gene are tandemly located on chromosome 19. FEBS Lett 247 1 (1989) 123-126
34. Riegman P., Vlietstra R., van der Korput J., Romijn J., and Trapman J. Characterization of the prostate-specific antigen gene: A novel human kallikrein-like gene. Biochem Biophys Res Commun 159 1 (1989) 95-102
35. Schedlich L., Bennetts B., and Morris B. Primary structure of a human glandular kallikrein gene. DNA 6 5 (1987) 429-437
36. Lundwall A., and Lilja H. Molecular cloning of human prostate specific antigen cDNA. FEBS Lett 214 2 (1987) 317-322
37. Lundwall A. Characterization of the gene for prostate-specific antigen, a human glandular kallikrein. Biochem Biophys Res Commun 161 3 (1989) 1151-1159
38. Takayama T., Fujikawa K., and Davie E. Characterization of the precursor of prostate-specific antigen. Activation by trypsin and by human glandular kallikrein. J Biol Chem 272 34 (1997) 21582-21588
39. Lovgren J., Rajakoski K., Karp M., Lundwall A., and Lilja H. Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem Biophys Res Commun 238 2 (1997) 549-555
40. Paju A., Bjartell A., Zhang W., et al. Expression and characterization of trypsinogen produced in the human male genital tract. Am J Pathol 157 6 (2000) 2011-2021
41. Takayama T., McMullen B., Nelson P., Matsumura M., and Fujikawa K. Characterization of hK4 (prostase), a prostate-specific serine protease: Activation of the precursor of prostate specific antigen (pro-PSA) and single-chain urokinase-type plasminogen activator and degradation of prostatic acid phosphatase. Biochemistry 40 50 (2001) 15341-15348
42. Takayama T., Carter C., and Deng T. Activation of prostate-specific antigen precursor (pro-PSA) by prostin, a novel human prostatic serine protease identified by degenerate PCR. Biochemistry 40 6 (2001) 1679-1687
43. Corey E., Brown L., Corey M., Buhler K., and Vessella R. LNCaP produces both putative zymogen and inactive, free form of prostate-specific antigen. Prostate 35 2 (1998) 135-143
44. Belanger A., van Halbeek H., Graves H., et al. Molecular mass and carbohydrate structure of prostate specific antigen: Studies for establishment of an international PSA standard. Prostate 27 4 (1995) 187-197
45. Wang M., Papsidero L., Kuriyama M., Valenzuela L., Murphy G., and Chu T. Prostate antigen: A new potential marker for prostatic cancer. Prostate 2 1 (1981) 89-96
46. Wang T., Rittenhouse H., Wolfert R., Lynne C., and Brackett N. PSA concentrations in seminal plasma. Clin Chem 44 4 (1998) 895-896
47. Vihinen M. Modeling of prostate specific antigen and human glandular kallikrein structures. Biochem Biophys Res Commun 204 3 (1994) 1251-1256
48. Bridon D., and Dowell B. Structural comparison of prostate-specific antigen and human glandular kallikrein using molecular modeling. Urology 45 5 (1995) 801-806
49. Villoutreix B., Getzoff E., and Griffin J. A structural model for the prostate disease marker, human prostate-specific antigen. Protein Sci 3 11 (1994) 2033-2044
50. Christensson A., Laurell C., and Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur J Biochem 194 3 (1990) 755-763
51. Denmeade S., Lou W., Lovgren J., Malm J., Lilja H., and Isaacs J. Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen. Cancer Res 57 21 (1997) 4924-4930
52. Coombs G., Bergstrom R., Pellequer J., et al. Substrate specificity of prostate-specific antigen (PSA). Chem Biol 5 9 (1998) 475-488
53. Robert M., Gibbs B., Jacobson E., and Gagnon C. Characterization of prostate-specific antigen proteolytic activity on its major physiological substrate, the sperm motility inhibitor precursor/semenogelin I. Biochemistry 36 13 (1997) 3811-3819
54. Qiu S., Young C., Bilhartz D., et al. In situ hybridization of prostate-specific antigen mRNA in human prostate. J Urol 144 6 (1990) 1550-1556
55. Young C., Montgomery B., Andrews P., Qui S., Bilhartz D., and Tindall D. Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. Cancer Res 51 14 (1991) 3748-3752
56. Riegman P., Vlietstra R., van der Korput J., Brinkmann A., and Trapman J. The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol Endocrinol 5 12 (1991) 1921-1930
57. Lee C., Sutkowski D., Sensibar J., et al. Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone. Endocrinology 136 2 (1995) 796-803
58. Henttu P., and Vihko P. Growth factor regulation of gene expression in the human prostatic carcinoma cell line LNCaP. Cancer Res 53 5 (1993) 1051-1058
59. Culig Z., Hobisch A., Cronauer M., et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54 20 (1994) 5474-5478
60. Zhang W., Leinonen J., Kalkkinen N., Dowell B., and Stenman U. Purification and characterization of different molecular forms of prostate-specific antigen in human seminal fluid. Clin Chem 41 11 (1995) 1567-1573
61. Schaller J., Akiyama K., Tsuda R., Hara M., Marti T., and Rickli E. Isolation, characterization and amino-acid sequence of gamma-seminoprotein, a glycoprotein from human seminal plasma. Eur J Biochem 170 1/2 (1987) 111-120
62. Kamoshida S., and Tsutsumi Y. Extraprostatic localization of prostatic acid phosphatase and prostate-specific antigen: Distribution in cloacogenic glandular epithelium and sex-dependent expression in human anal gland. Hum Pathol 21 11 (1990) 1108-1111
63. James G., Pudek M., Berean K., Diamandis E., and Archibald B. Salivary duct carcinoma secreting prostate-specific antigen. Am J Clin Pathol 106 2 (1996) 242-247
64. Clements J., and Mukhtar A. Glandular kallikreins and prostate-specific antigen are expressed in the human endometrium. J Clin Endocrinol Metab 78 6 (1994) 1536-1539
65. Yu H., and Diamandis E. Prostate-specific antigen in milk of lactating women. Clin Chem 41 1 (1995) 54-58
66. Olsson A., Bjartell A., Lilja H., and Lundwall A. Expression of prostate-specific antigen (PSA) and human glandular kallikrein 2 (hK2) in ileum and other extraprostatic tissues. Int J Cancer 113 2 (2005) 290-297
67. Yu H., Giai M., Diamandis E., et al. Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Res 55 10 (1995) 2104-2110
68. Diamandis E. Elevated serum prostate-specific antigen levels in a woman with metastatic breast cancer. N Engl J Med 343 12 (2000) 890-891
69. Levesque M., Yu H., D'Costa M., Tadross L., and Diamandis E. Immunoreactive prostate-specific antigen in lung tumors. J Clin Lab Anal 9 6 (1995) 375-379
70. Levesque M., Hu H., D'Costa M., and Diamandis E. Prostate-specific antigen expression by various tumors. J Clin Lab Anal 9 2 (1995) 123-128
71. Yu H., and Diamandis E. Ultrasensitive time-resolved immunofluorometric assay of prostate-specific antigen in serum and preliminary clinical studies. Clin Chem 39 10 (1993) 2108-2114
72. Diamandis E., Yu H., and Melegos D. Ultrasensitive prostate-specific antigen assays and their clinical application. Clin Chem 42 6 Pt 1 (1996) 853-857
73. Diamandis E., and Yu H. Nonprostatic sources of prostate-specific antigen. Urol Clin North Am 24 2 (1997) 275-282
74. Abrahamsson P., Lilja H., Falkmer S., and Wadstrom L. Immunohistochemical distribution of the three predominant secretory proteins in the parenchyma of hyperplastic and neoplastic prostate glands. Prostate 12 1 (1988) 39-46
75. Stenman U. Prostate-specific antigen, clinical use and staging: An overview. Br J Urol 79 Suppl 1 (1997) 53-60
76. Stenman U., Leinonen J., Zhang W., and Finne P. Prostate-specific antigen. Semin Cancer Biol 9 2 (1999) 83-93
77. Sobel R., and Sadar M. Cell lines used in prostate cancer research: A compendium of old and new lines-Part 2. J Urol 173 2 (2005) 360-372
78. Sobel R., and Sadar M. Cell lines used in prostate cancer research: A compendium of old and new lines-Part 1. J Urol 173 2 (2005) 342-359
79. Denmeade S., Sokoll L., Chan D., Khan S., and Isaacs J. Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models. Prostate 48 1 (2001) 1-6
80. Horoszewicz J., Leong S., Kawinski E., et al. LNCaP model of human prostatic carcinoma. Cancer Res 43 4 (1983) 1809-1818
81. Vaisanen V., Lovgren J., Hellman J., Piironen T., Lilja H., and Pettersson K. Characterization and processing of prostate specific antigen (hK3) and human glandular kallikrein (hK2) secreted by LNCaP cells. Prostate Cancer Prostatic Dis 2 2 (1999) 91-97
82. Veldscholte J., Ris-Stalpers C., Kuiper G., et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 173 2 (1990) 534-540
83. Espana F., Gilabert J., Estelles A., Romeu A., Aznar J., and Cabo A. Functionally active protein C inhibitor/plasminogen activator inhibitor-3 (PCI/PAI-3) is secreted in seminal vesicles, occurs at high concentrations in human seminal plasma and complexes with prostate-specific antigen. Thromb Res 64 3 (1991) 309-320
84. Leinonen J., Zhang W., and Stenman U. Complex formation between PSA isoenzymes and protease inhibitors. J Urol 155 3 (1996) 1099-1103
85. Zhang W., Finne P., Leinonen J., Vesalainen S., Nordling S., and Stenman U. Measurement of the complex between prostate-specific antigen and alpha1-protease inhibitor in serum. Clin Chem 45 6 Pt 1 (1999) 814-821
86. Christensson A., and Lilja H. Complex formation between protein C inhibitor and prostate-specific antigen in vitro and in human semen. Eur J Biochem 220 1 (1994) 45-53
87. Lilja H., Oldbring J., Rannevik G., and Laurell C. Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen. J Clin Invest 80 2 (1987) 281-285
88. Fortier A., Nelson B., Grella D., and Holaday J. Antiangiogenic activity of prostate-specific antigen. J Natl Cancer Inst 91 19 (1999) 1635-1640
89. Heidtmann H., Nettelbeck D., Mingels A., Jager R., Welker H., and Kontermann R. Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen. Br J Cancer 81 8 (1999) 1269-1273
90. Fortier A., Holaday J., Liang H., et al. Recombinant prostate specific antigen inhibits angiogenesis in vitro and in vivo. Prostate 56 3 (2003) 212-219
91. Balbay M., Juang P., Llansa N., et al. Stable transfection of human prostate cancer cell line PC-3 with prostate specific antigen induces apoptosis both in vivo and in vitro (Abstract). Proc Am Assoc Cancer Res 40 (1999) 225-226
92. Yoshida E., Ohmura S., Sugiki M., Maruyama M., and Mihara H. Prostate-specific antigen activates single-chain urokinase-type plasminogen activator. Int J Cancer 63 6 (1995) 863-865
93. Killian C., Corral D., Kawinski E., and Constantine R. Mitogenic response of osteoblast cells to prostate-specific antigen suggests an activation of latent TGF-beta and a proteolytic modulation of cell adhesion receptors. Biochem Biophys Res Commun 192 2 (1993) 940-947
94. Cohen P., Graves H., Peehl D., Kamarei M., Giudice L., and Rosenfeld R. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 75 4 (1992) 1046-1053
95. Rehault S., Monget P., Mazerbourg S., et al. Insulin-like growth factor binding proteins (IGFBPs) as potential physiological substrates for human kallikreins hK2 and hK3. Eur J Biochem 268 10 (2001) 2960-2968
96. Koistinen H., Paju A., Koistinen R., et al. Prostate-specific antigen and other prostate-derived proteases cleave IGFBP-3, but prostate cancer is not associated with proteolytically cleaved circulating IGFBP-3. Prostate 50 2 (2002) 112-118
97. Webber M., Waghray A., and Bello D. Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clin Cancer Res 1 10 (1995) 1089-1094
98. Stege R., Grande M., Carlstrom K., Tribukait B., and Pousette A. Prognostic significance of tissue prostate-specific antigen in endocrine-treated prostate carcinomas. Clin Cancer Res 6 1 (2000) 160-165
99. Yuan J., Coplen D., Petros J., et al. Effects of rectal examination, prostatic massage, ultrasonography and needle biopsy on serum prostate specific antigen levels. J Urol 147 3 Pt 2 (1992) 810-814
100. Oesterling J., Rice D., Glenski W., and Bergstralh E. Effect of cystoscopy, prostate biopsy, and transurethral resection of prostate on serum prostate-specific antigen concentration. Urology 42 3 (1993) 276-282
101. Graves H., Wehner N., and Stamey T. Comparison of a polyclonal and monoclonal immunoassay for PSA: Need for an international antigen standard. J Urol 144 6 (1990) 1516-1522
102. Zhou A., Tewari P., Bluestein B., Caldwell G., and Larsen F. Multiple forms of prostate-specific antigen in serum: Differences in immunorecognition by monoclonal and polyclonal assays. Clin Chem 39 12 (1993) 2483-2491
103. Stamey T. Second Stanford Conference on International Standardization of Prostate-Specific Antigen Immunoassays: September 1 and 2, 1994. Urology 45 2 (1995) 173-184
104. Stenman U., Leinonen J., and Zhang W. Standardization of PSA determinations. Scand J Clin Lab Invest Suppl 221 45 (1995) 45-51
105. Rafferty B., Rigsby P., Rose M., Stamey T., and Gaines Das R. Reference reagents for prostate-specific antigen (PSA): Establishment of the first international standards for free PSA and PSA (90:10). Clin Chem 46 9 (2000) 1310-1317
106. Link R., Shariat S., Nguyen C., et al. Variation in prostate specific antigen results from 2 different assay platforms: Clinical impact on 2304 patients undergoing prostate cancer screening. J Urol 171 6 Pt 1 (2004) 2234-2238
107. Pettersson K., Piironen T., Seppala M., et al. Free and complexed prostate-specific antigen (PSA): In vitro stability, epitope map, and development of immunofluorometric assays for specific and sensitive detection of free PSA and PSA-alpha 1-antichymotrypsin complex (see comments). Clin Chem 41 10 (1995) 1480-1488
108. Stenman U., Paus E., Allard W., et al. Summary report of the TD-3 workshop: Characterization of 83 antibodies against prostate-specific antigen. Tumour Biol 20 Suppl 1 (1999) 1-12
109. Villoutreix B., Lilja H., Pettersson K., Lovgren T., and Teleman O. Structural investigation of the alpha-1-antichymotrypsin: Prostate-specific antigen complex by comparative model building. Protein Sci 5 5 (1996) 836-851
110. Leinonen J., Zhang W., Paus E., and Stenman U. Reactivity of 77 antibodies to prostate-specific antigen with isoenzymes and complexes of prostate-specific antigen. Tumour Biol 1 28 (1999) 28-34
111. Nilsson O., Andersson I., Peter A., and Karlsson B. Characterization of antibodies to prostate-specific antigen. Tumour Biol 1 43 (1999) 43-51
112. Piironen T., Lovgren J., Karp M., et al. Immunofluorometric assay for sensitive and specific measurement of human prostatic glandular kallikrein (hK2) in serum. Clin Chem 42 7 (1996) 1034-1041
113. Catalona W., Smith D., and Ornstein D. Prostate cancer detection in men with serum PSA concentrations of 2.6-4.0 ng/ml and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 277 18 (1997) 1452-1455
114. Stamey T. Some comments on progress in the standardization of immunoassays for prostate-specific antigen. Br J Urol 79 Suppl 1 (1997) 49-52
115. Catalona W., Smith D., Ratliff T., and Basler J. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 270 8 (1993) 948-954
116. Oesterling J., Jacobsen S., and Cooner W. The use of age-specific reference ranges for serum prostate specific antigen in men 60 years old or older. J Urol 153 4 (1995) 1160-1163
117. Lodding P., Aus G., Bergdahl S., et al. Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng/ml. Prostate specific antigen. J Urol 159 3 (1998) 899-903
118. Schroder F., van der Cruijsen-Koeter I., de Koning H., Vis A., Hoedemaeker R., and Kranse R. Prostate cancer detection at low prostate specific antigen. J Urol 163 3 (2000) 806-812
119. Oesterling J., Cooner W., Jacobsen S., Guess H., and Lieber M. Influence of patient age on the serum PSA concentration. An important clinical observation. Urol Clin North Am 20 4 (1993) 671-680
120. Oesterling J., Jacobsen S., Klee G., et al. Free, complexed and total serum prostate specific antigen: The establishment of appropriate reference ranges for their concentrations and ratios. J Urol 154 3 (1995) 1090-1095
121. Babaian R., Kojima M., Ramirez E., and Johnston D. Comparative analysis of prostate specific antigen and its indexes in the detection of prostate cancer. J Urol 156 2 Pt 1 (1996) 432-437
122. Leinonen J., Lovgren T., Vornanen T., and Stenman U. Double-label time-resolved immunofluorometric assay of prostate-specific antigen and of its complex with alpha 1-antichymotrypsin. Clin Chem 39 10 (1993) 2098-2103
123. Christensson A., Bjork T., Nilsson O., et al. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol 150 1 (1993) 100-105
124. Espana F., Martinez M., Sanchez-Cuenca J., Vera C., Estelles A., and Jimenez-Cruz J. Prostate-specific antigen and its complexes with alpha 1-antichymotrypsin in the plasma of patients with prostatic disease. Eur Urol 30 4 (1996) 512-518
125. Kuriyama M., Abrahamsson P., Imai K., et al. Determination of serum prostate-specific antigen-alpha1-antichymotrypsin complex for diagnosis of prostate cancer in Japanese cases. Scand J Urol Nephrol 35 1 (2001) 5-10
126. Wu J., Wilson L., Zhang P., Meikle A., and Stephenson R. Correlation of serum concentrations of PSA-ACT complex with total PSA in random and serial specimens from patients with BPH and prostate cancer. J Clin Lab Anal 9 1 (1995) 15-24
127. Matsumoto K., Konishi N., Samori T., et al. ELISA for a complexed antigen with a monoclonal antibody blocking reaction with the free antigen-assay-specific for complexed prostate-specific antigen. J Immunol Methods 234 1-2 (2000) 99-106
128. Wu J., Zhang P., Liu G., and Wilson L. Development of an immunoassay specific for the PSA-ACT complex without the problem of high background. J Clin Lab Anal 12 1 (1998) 14-19
129. Chan D., Kelley C., Partin A., et al. PSA-ACT immunoassay: Problems and solutions. Clin Chem 42 6 (1996) S255
130. Chen Z., Chen H., and Stamey T. Monoclonal antibodies 2F5 and 4G10 against prostate specific antigen (PSA) complexed to alpha1-antichymotrypsin. J Urol 160 3 Pt 1 (1998) 870-875
131. Wan X., Xu Y., Ware J., and Kennedy A. Three immunoassays based on monoclonal antibodies specific for prostate specific antigen (PSA), alpha-1-antichymotrypsin (ACT), and the PSA-ACT complex. Prostate 56 2 (2003) 131-141
132. Zhu L., Leinonen J., Zhang W., Finne P., and Stenman U. Dual-label immunoassay for simultaneous measurement of prostate-specific antigen (PSA)-alpha1-antichymotrypsin complex together with free or total PSA. Clin Chem 49 1 (2003) 97-103
133. Brawer M., Meyer G., Letran J., et al. Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology 52 3 (1998) 372-378
134. Miller M., O'Dowd G., Partin A., and Veltri R. Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: Impact of changing disease demographics. Urology 57 6 (2001) 1105-1111
135. Okihara K., Ukimura O., Nakamura T., et al. Can complexed prostate specific antigen enhance prostate cancer detection in Japanese men?. Eur Urol 46 1 (2004) 57-64
136. Lein M., Kwiatkowski M., Semjonow A., et al. A multicenter clinical trial on the use of complexed prostate specific antigen in low prostate specific antigen concentrations. J Urol 170 4 Pt 1 (2003) 1175-1179
137. Chen Z., Komatsu K., Prestigiacomo A., and Stamey T. Addition of purified prostate specific antigen to serum from female subjects: Studies on the relative inhibition by alpha 2-macroglobulin and alpha 1-antichymotrypsin. J Urol 156 4 (1996) 1357-1363
138. Miyata K., Nakamura M., and Tomoda K. Interaction between Serratia protease and human plasma alpha 2 macroglobulin. J Biochem (Tokyo) 89 4 (1981) 1231-1237
139. Lin V., Wang S., Boetticher N., et al. Alpha(2) macroglobulin, a PSA binding protein, is expressed in human prostate stroma. Prostate 63 3 (2005) 299-308
140. Baumgart Y., Otto A., Schafer A., et al. Characterization of novel monoclonal antibodies for prostate-specific antigen (PSA) with potency to recognize PSA bound to alpha 2-macroglobulin. Clin Chem 51 1 (2005) 84-92
141. Catalona W., Bartsch G., Rittenhouse H., et al. Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. J Urol 171 6 Pt 1 (2004) 2239-2244
142. Mikolajczyk S., Catalona W., Evans C., et al. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem 50 6 (2004) 1017-1025
143. Canto E., Singh H., Shariat S., et al. Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer. Urology 63 5 (2004) 905-910 discussion 910-911.
144. Khan M., Sokoll L., Chan D., et al. Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%. Urology 64 6 (2004) 1160-1164
145. Mikolajczyk S., Grauer L., Millar L., et al. A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology 50 5 (1997) 710-714
146. Noldus J., Chen Z., and Stamey T. Isolation and characterization of free form prostate specific antigen (f-PSA) in sera of men with prostate cancer. J Urol 158 4 (1997) 1606-1609
147. Charrier J., Tournel C., Michel S., Dalbon P., and Jolivet M. Two-dimensional electrophoresis of prostate-specific antigen in sera of men with prostate cancer or benign prostate hyperplasia. Electrophoresis 20 4/5 (1999) 1075-1081
148. Peter J., Unverzagt C., Krogh T., Vorm O., and Hoesel W. Identification of precursor forms of free prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry. Cancer Res 61 3 (2001) 957-962
149. Mikolajczyk S., and Rittenhouse H. Pro PSA: A more cancer specific form of prostate specific antigen for the early detection of prostate cancer. Keio J Med 52 2 (2003) 86-91
150. Chan T., Mikolajczyk S., Lecksell K., et al. Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen. Urology 62 1 (2003) 177-181
151. Sokoll L., Chan D., Mikolajczyk S., et al. Proenzyme PSA for the early detection of prostate cancer in the 2.5-4.0 ng/ml total PSA range: Preliminary analysis. Urology 61 2 (2003) 274-276
152. Catalona W., Bartsch G., Rittenhouse H., et al. Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J Urol 170 6 Pt 1 (2003) 2181-2185
153. Chen Z., Chen H., and Stamey T. Prostate specific antigen in benign prostatic hyperplasia: Purification and characterization. J Urol 157 6 (1997) 2166-2170
154. Hilz H., Noldus J., Hammerer P., Buck F., Luck M., and Huland H. Molecular heterogeneity of free PSA in sera of patients with benign and malignant prostate tumors. Eur Urol 36 4 (1999) 286-292
155. Mikolajczyk S., Millar L., Marker K., et al. Seminal plasma contains "BPSA," a molecular form of prostate-specific antigen that is associated with benign prostatic hyperplasia. Prostate 45 3 (2000) 271-276
156. Linton H., Marks L., Millar L., Knott C., Rittenhouse H., and Mikolajczyk S. Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease. Clin Chem 49 2 (2003) 253-259
157. Mikolajczyk S., Millar L., Wang T., et al. "BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology 55 1 (2000) 41-45
158. Nurmikko P., Vaisanen V., Piironen T., Lindgren S., Lilja H., and Pettersson K. Production and characterization of novel anti-prostate-specific antigen (PSA) monoclonal antibodies that do not detect internally cleaved Lys145-Lys146 inactive PSA. Clin Chem 46 10 (2000) 1610-1618
159. Lilja H., Abrahamsson P., and Lundwall A. Semenogelin, the predominant protein in human semen. Primary structure and identification of closely related proteins in the male accessory sex glands and on the spermatozoa. J Biol Chem 264 3 (1989) 1894-1900
160. Stenman U. Immunoassay standardisation. In: Price C., and Newman D. (Eds). Principles and Practice of Immunoassay. 2nd ed. (1997), Macmillan, London 245-268
161. Wu P., Leinonen J., Koivunen E., Lankinen H., and Stenman U. Identification of novel prostate-specific antigen-binding peptides modulating its enzyme activity. Eur J Biochem 267 20 (2000) 6212-6220
162. Wu P., Stenman U., Pakkala M., Narvanen A., and Leinonen J. Separation of enzymatically active and inactive prostate-specific antigen (PSA) by peptide affinity chromatography. Prostate 58 4 (2004) 345-353
163. Owens R., Gesellchen P., Houchins B., and DiMarchi R. The rapid identification of HIV protease inhibitors through the synthesis and screening of defined peptide mixtures. Biochem Biophys Res Commun 181 1 (1991) 402-408
164. Eichler J., and Houghten R. Identification of substrate-analog trypsin inhibitors through the screening of synthetic peptide combinatorial libraries. Biochemistry 32 41 (1993) 11035-11041
165. Koivunen E., Arap W., Valtanen H., et al. Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol 17 8 (1999) 768-774
166. Felici F., Castagnoli L., Musacchio A., Jappelli R., and Cesareni G. Selection of antibody ligands from a large library of oligopeptides expressed on a multivalent exposition vector. J Mol Biol 222 2 (1991) 301-310
167. Koivunen E., Arap W., Rajotte D., Lahdenranta J., and Pasqualini R. Identification of receptor ligands with phage display peptide libraries. J Nucl Med 40 5 (1999) 883-888
168. Doorbar J., and Winter G. Isolation of a peptide antagonist to the thrombin receptor using phage display. J Mol Biol 244 4 (1994) 361-369
169. Kay B., Winter J., and McCafferty J. Phage Display of Peptides and Proteins: A Laboratory Manual (1996), Academic Press, San Diego, CA
170. Smith G. Filamentous fusion phage: Novel expression vectors that display cloned antigens on the virion surface. Science 228 4705 (1985) 1315-1317
171. Wu P., Zhu L., Stenman U., and Leinonen J. Immunopeptidometric assay for enzymatically active prostate-specific antigen. Clin Chem 50 1 (2004) 125-129 Epub 2003 Nov 18.
172. Nam J., Thaxton C., and Mirkin C. Nanoparticle-based bio-bar codes for the ultrasensitive detection of proteins. Science 301 5641 (2003) 1884-1886
173. Jung K., Reiche J., Boehme A., et al. Analysis of subforms of free prostate-specific antigen in serum by two-dimensional gel electrophoresis: Potential to improve diagnosis of prostate cancer. Clin Chem 50 12 (2004) 2292-2301
174. Moreno J., Croce C., Fischer R., et al. Detection of hematogenous micrometastasis in patients with prostate cancer. Cancer Res 52 21 (1992) 6110-6112
175. Gomella L., Raj G., and Moreno J. Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer. J Urol 158 2 (1997) 326-337
176. Schamhart D., Maiazza R., and Kurth K. Identification of circulating prostate cancer cells: A challenge to the clinical implementation of molecular biology (review). Int J Oncol 26 3 (2005) 565-577
177. Katz A., de Vries G., Begg M., et al. Enhanced reverse transcriptase-polymerase chain reaction for prostate specific antigen as an indicator of true pathologic stage in patients with prostate cancer. Cancer 75 7 (1995) 1642-1648
178. Katz A., Olsson C., Raffo A., et al. Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. Urology 43 6 (1994) 765-775
179. Chen B., Loberg R., Neeley C., et al. Preliminary study of immunomagnetic quantification of circulating tumor cells in patients with advanced disease. Urology 65 3 (2005) 616-621
180. Lintula S., Vesalainen S., Rannikko A., et al. Quantification of prostate specific antigen mRNA levels in circulation after prostatic surgery and endocrine treatment by quantitative reverse transcription-polymerase chain reaction. Scand J Clin Lab Invest 64 2 (2004) 93-100
181. Ghossein R., Rosai J., Scher H., et al. Prognostic significance of detection of prostate-specific antigen transcripts in the peripheral blood of patients with metastatic androgen-independent prostatic carcinoma. Urology 50 1 (1997) 100-105
182. Ghossein R., Scher H., Gerald W., et al. Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: Clinical implications. J Clin Oncol 13 5 (1995) 1195-1200
183. Smith M., Biggar S., and Hussain M. Prostate-specific antigen messenger RNA is expressed in non-prostate cells: Implications for detection of micrometastases. Cancer Res 55 12 (1995) 2640-2644
184. Lintula S., and Stenman U. The expression of prostate-specific membrane antigen in peripheral blood leukocytes. J Urol 157 5 (1997) 1969-1972
185. Catalona W., Smith D., Wolfert R., et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 274 15 (1995) 1214-1220
186. Bangma C., Rietbergen J., Kranse R., Blijenberg B., Petterson K., and Schröder F. The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population. J Urol 157 6 (1997) 2191-2196
187. Hosmer D., and Lemeshow S. Applied Logistic Regression. 2nd ed. (2000), Wiley, New York
188. Finne P., Finne R., and Stenman U. Neural network analysis of clinicopathological factors in urological disease: A critical evaluation of available techniques. BJU Int 88 8 (2001) 825-831
189. Carlson G., Calvanese C., and Partin A. An algorithm combining age, total prostate-specific antigen (PSA), and percent free PSA to predict prostate cancer: Results on 4298 cases. Urology 52 3 (1998) 455-461
190. Virtanen A., Gomari M., Kranse R., and Stenman U. Estimation of prostate cancer probability by logistic regression: Free and total prostate-specific antigen, digital rectal examination, and heredity are significant variables. Clin Chem 45 7 (1999) 987-994
191. Finne P., Finne R., Auvinen A., et al. Predicting the outcome of prostate biopsy in screen-positive men by a multilayer perceptron network. Urology 56 3 (2000) 418-422
192. Djavan B., Remzi M., Zlotta A., Seitz C., Snow P., and Marberger M. Novel artificial neural network for early detection of prostate cancer. J Clin Oncol 20 4 (2002) 921-929
193. Stephan C., Cammann H., Semjonow A., et al. Multicenter evaluation of an artificial neural network to increase the prostate cancer detection rate and reduce unnecessary biopsies. Clin Chem 48 8 (2002) 1279-1287
194. Stephan C., Jung K., Cammann H., et al. An artificial neural network considerably improves the diagnostic power of percent free prostate-specific antigen in prostate cancer diagnosis: Results of a 5-year investigation. Int J Cancer 99 3 (2002) 466-473
195. Finne P., Finne R., Bangma C., et al. Algorithms based on prostate-specific antigen (PSA), free PSA, digital rectal examination and prostate volume reduce false-positive PSA results in prostate cancer screening. Int J Cancer 111 2 (2004) 310-315
196. Tewari A., and Narayan P. Novel staging tool for localized prostate cancer: A pilot study using genetic adaptive neural networks. J Urol 160 2 (1998) 430-436
197. Batuello J., Gamito E., Crawford E., et al. Artificial neural network model for the assessment of lymph node spread in patients with clinically localized prostate cancer. Urology 57 3 (2001) 481-485
198. Han M., Snow P., Brandt J., and Partin A. Evaluation of artificial neural networks for the prediction of pathologic stage in prostate carcinoma. Cancer 91 S8 (2001) 1661-1666
199. Snow P., Smith D., and Catalona W. Artificial neural networks in the diagnosis and prognosis of prostate cancer: A pilot study. J Urol 152 5 Pt 2 (1994) 1923-1926
200. Han M., Snow P., Epstein J., et al. A neural network predicts progression for men with Gleason score 3 + 4 versus 4 + 3 tumors after radical prostatectomy. Urology 56 6 (2000) 994-999
201. Zupan B., Demsar J., Kattan M., Beck J., and Bratko I. Machine learning for survival analysis: A case study on recurrence of prostate cancer. Artif Intell Med 20 1 (2000) 59-75
202. Schwarzer G., and Schumacher M. Artificial neural networks for diagnosis and prognosis in prostate cancer. Semin Urol Oncol 20 2 (2002) 89-95